Vli
BRAF Gene Mutation
West Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the BRAF Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE TriHealth Inc. | Phase 2 | B |
gsk1120212 Rina Plattner | Phase 2 | B |
Cyclophosphamide University of Southern California | Phase 2 | B |
Dabrafenib Rina Plattner | Phase 2 | B |
Pembrolizumab University of Southern California | Phase 2 | B |
View all 22 →
Same molecule, other indications
Vli is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →